---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349182"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2026-08-13T20:10:16+00:00"
generated_at: "2026-08-13T20:12:38.459625+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium Q2 2026 net loss $4.7M; cash $57.2M funds operations into 2029

## Summary
- Net loss $4.7M ($0.04/share) vs $5.7M ($0.16/share) in Q2 2025; R&D spend down to $2.8M from $4.1M.
- Cash and equivalents $57.2M at June 30, 2026, down from $61.3M at March 31, 2026; runway into 2029.
- EQ504 Phase 1 proof-of-mechanism study expected to start Q4 2026; topline data ~6 months later.
- IND-enabling work initiated for inhaled EQ504 (lung disease) and oral EQ302 (celiac disease).
- Clinical Advisory Board for EQ504 ulcerative colitis program chaired by Prof. Bruce Sands (Mount Sinai).

## SEC filing metadata
- accession: 0001193125-26-349182
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2026-08-13T20:10:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/0001193125-26-349182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349182
- JSON: https://secwatch.observer/filing/0001193125-26-349182.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.